10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-Mnk2a Antibody

Our Anti-Mnk2a rabbit polyclonal primary antibody from PhosphoSolutions is produced in-house. It det

Catalog # AN1457

Product Information

Application	WB
Primary Accession	Q9HBH9
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Calculated MW	51875

Additional Information

Gene ID	2872
Other Names	ADCAD1 antibody, MADS box transcription enhancer factor 2 polypeptide A (myocyte enhancer factor 2A) antibody, MEF2 antibody, MEF2A antibody, MEF2A_HUMAN antibody, Myocyte enhancer factor 2A antibody, Myocyte-specific enhancer factor 2A antibody, RSRFC4 antibody, RSRFC9 antibody, Serum response factor like protein 1 antibody, Serum response factor-like protein 1 antibody
Target/Specificity	MAP kinase-interacting kinases Mnk1 and Mnk2 are activated by the MAP kinases, ERK and p38 (Waskiewicz et al., 1997). Additionally, Mnk1 and Mnk2 have been shown to phosphorylate the translation initiation factor eIF4E (Fukunaga and Hunter 1997; Waskiewicz et al., 1997). Alternative splicing of the MKNK2 gene results in two isoforms with different C-termini: one that has a MAPK-binding domain, Mnk2a, and one that does not, Mnk2b (Parra et al., 2005). Recent studies have indicated that Mnk2a has tumor suppressive activity while Mnk2b is pro-oncogenic (Maimon et al., 2014).
Dilution	WB~~1:1000
Format	Antigen Affinity Purified from Pooled Serum
Storage	Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	Anti-Mnk2a Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
Shipping	Blue Ice

Background

MAP kinase-interacting kinases Mnk1 and Mnk2 are activated by the MAP kinases, ERK and p38 (Waskiewicz

et al., 1997). Additionally, Mnk1 and Mnk2 have been shown to phosphorylate the translation initiation factor eIF4E (Fukunaga and Hunter 1997; Waskiewicz et al., 1997). Alternative splicing of the MKNK2 gene results in two isoforms with different C-termini: one that has a MAPK-binding domain, Mnk2a, and one that does not, Mnk2b (Parra et al., 2005). Recent studies have indicated that Mnk2a has tumor suppressive activity while Mnk2b is pro-oncogenic (Maimon et al., 2014).